May 2026
📣 VC round data is live. Check it out!
Largest Biopharmaceuticals Public Companies in Taiwan
Benchmark revenue and EBITDA valuation multiples for public comps like
PharmaEssentia, Caliway Biopharmaceuticals, Lotus Pharmaceutical, Bora Pharmaceuticals and Center Laboratories.
 | PharmaEssentia Corp is engaged in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug pattern developments. It focuses on Hematology, Oncology, and Infectious Diseases. The company derives its revenue from the sales of medicine products. Geographically, the company generates maximum revenue from America, followed by Europe, Asia (excluding Taiwan), and Taiwan. | $27 | +89% | $10B | $9B | 18.6x | 53.7x | ||
| Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. Its pipeline candidates are CBL-514, CBA-539, and CBO-012. | $3 | +25% | $5B | $5B | 4291.4x | (508.3x) | ||
| Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. The only reportable segment of the company is the Pharmaceuticals business segment, which engages mainly in the research and development, manufacturing and sales of pharmaceutical products. It has a geographic presence in the United States, Malta, Taiwan, and Others. | $6 | -15% | $2B | $3B | 4.5x | 11.2x | ||
| Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Commercial sales segment, Contract Development & Manufacturing Organization segment, and Other segment. The majority of revenue is derived from the Commercial sales segment. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions. | $12 | -42% | $1B | $2B | 3.1x | 8.7x | ||
| Center Laboratories Inc is active in the healthcare sector. The company is engaged in the manufacture and sale of various Western medicines. The segments include: Pharmaceutical Division which includes manufacturing and sales of various Western Medicines; Biotechnology Venture Capital consists Investing in domestic and foreign biotechnology undertakings; Glac segment - Manufacture and sale of probiotic products and others. It geographically operates in Taiwan, China and Others. | $1 | +0% | $914M | $1B | 21.4x | 2.7x | ||
| Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The company's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, OB318, and others. Along with its subsidiaries, the company operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation segment. | $2 | -10% | $793M | $619M | 150.8x | (27.3x) | ||
| Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods. | $4 | -20% | $677M | $651M | 568.8x | (61.1x) | ||
| TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others. | $2 | -1% | $581M | $525M | 2.6x | 7.0x | ||
| Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment. | $1 | 0% | $491M | $477M | 2.4x | 12.5x | ||
| Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of COVID-19 vaccines and COVID-19 test kits and provides technical services on cellular therapy product quality and cell culture tests. | $1 | -8% | $488M | $441M | 22.6x | (113.7x) | ||
| Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process. | $1 | -59% | $477M | $464M | 359.4x | (4.2x) | ||
| YungShin Global Holding Co Ltd invests, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicine, and cosmetics. The company derives revenue from the sale of Human drugs, Health food, Animal drugs, and Others. The company generates the majority of its revenue from Human drugs. Geographically, the company generates the revenue from Taiwan, the USA, Japan, and China, out of which the majority of its revenue is generated from Taiwan. | $2 | -8% | $473M | $433M | 1.6x | 8.4x | ||
| CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs. | $2 | +72% | $464M | $399M | 8755.1x | (47.7x) | ||
| Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the cell preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses. | $4 | -14% | $429M | $416M | 12.8x | 23.9x | ||
| TaiMed Biologics Inc is a biotechnology company committed to have the expertise and capability in developing, manufacturing and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 (TMB-365 and TMB-380 combination), and Antibody-Drug Conjugates, ADCs. | $2 | -35% | $425M | $385M | 19.8x | (3501.8x) | ||
| Acepodia Inc is a clinical stage biotechnology company engaged to develop first-in-class cell therapies by using the Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients. | $0 | -26% | $240M | $128M | 21691.5x | (6.3x) | ||
| Adimmune Corp is a Taiwan-based company. It is engaged in the development, manufacture, and distribution of vaccines and other biological products. Its pipeline consists of products like AdimFlu-S (QIS) which is a vaccine intended for use in the prevention of influenza, and TetraFlu among others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the USA, China, and other regions. | $1 | -6% | $233M | $252M | 5.7x | (94.6x) | ||
| Savior Lifetec Corp is engaged in the research, development, design, manufacture, and sale of carbapenem generics, injection generics, controlled-release generics, development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms of the aforementioned products. The company also provides medicine manufacturer technology and services. The company geographically operates in four regions: the Americas, Asia, Taiwan, and Europe. | $1 | -9% | $189M | $144M | 3.8x | 7.1x | ||
| Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company’s main operating region is located in Taiwan. | $1 | -27% | $184M | $211M | 9.0x | (48.8x) | ||
| Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company along with its subsidiaries is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups such as disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan, China, Hong Kong, and Macau, the USA, and Korea. It generates a majority of its revenue from the Taiwan segment. | $2 | -24% | $166M | $172M | 2.6x | 12.1x | ||
| Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. The company's segments include the Drug Development segment and the Other segment. | $1 | -38% | $134M | $133M | 7.0x | 108.7x | ||
| Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia. | -- | -- | $127M | $164M | 1.1x | (4375.9x) | ||
| Spirit Scientific Co Ltd is engaged in precision regenerative medicine, specializing in platelet cryocrystallization technology and Bio Material Lyophilized Technology (BMLT). The company provides solutions for extracting high-concentration platelet growth factors, enabling safe, flexible, and long-term storage therapies. Spirit Biotech delivers cutting-edge autologous healing reagent preparation services, along with OEM and ODM models. With a focus on unmet medical needs, the company transforms patented technologies into scalable solutions, advancing the future of regenerative healthcare. | $2 | -- | $29M | $20M | 2.3x | 11.3x | ||
| Median | $2 | -10% | $473M | $433M | 9.0x | 2.7x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.